Page last updated: 2024-10-16

adenine and Dyslipidemias

adenine has been researched along with Dyslipidemias in 18 studies

Dyslipidemias: Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL.

Research Excerpts

ExcerptRelevanceReference
"The aim of this study was to demonstrate how tenofovir alafenamide (TAF) and other hepatitis B treatment drugs differentially impact lipid profiles in chronic hepatitis B patients."9.41Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis. ( Hwang, EG; Jung, EA; Kim, SG; Kim, YS; Yoo, JJ, 2023)
" Because the metabolism of pravastatin is independent of the cytochrome P450 CYP3A4, this drug has become the preferred statin for treatment of dyslipidemia associated with human immunodeficiency virus (HIV) infection, with no cases of serious toxicity such as rhabdomyolysis reported to date."7.75Rhabdomyolysis in an HIV-infected patient on anti-retroviral therapy precipitated by high-dose pravastatin. ( Cope, D; Iskander, E; Mikhail, N, 2009)
" Healthy volunteer studies have demonstrated a decrease in glucose disposal associated with dosing with specific antiretrovirals."6.75Effect of boosted fosamprenavir or lopinavir-based combinations on whole-body insulin sensitivity and lipids in treatment-naive HIV-type-1-positive men. ( Back, DJ; Boffito, M; Jackson, AG; Mandalia, S; Moyle, GJ; Randell, PA; Taylor, J; Tjia, JF, 2010)
"The aim of this study was to demonstrate how tenofovir alafenamide (TAF) and other hepatitis B treatment drugs differentially impact lipid profiles in chronic hepatitis B patients."5.41Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis. ( Hwang, EG; Jung, EA; Kim, SG; Kim, YS; Yoo, JJ, 2023)
" Because the metabolism of pravastatin is independent of the cytochrome P450 CYP3A4, this drug has become the preferred statin for treatment of dyslipidemia associated with human immunodeficiency virus (HIV) infection, with no cases of serious toxicity such as rhabdomyolysis reported to date."3.75Rhabdomyolysis in an HIV-infected patient on anti-retroviral therapy precipitated by high-dose pravastatin. ( Cope, D; Iskander, E; Mikhail, N, 2009)
" nevirapine on the same background, in naïve HIV-1-infected patients) study compared prospectively ritonavir-boosted atazanavir (ATZ/r) 300 mg/100 mg once daily (qd) with immediate release nevirapine (NVP) 200 mg twice daily or 400 mg qd, each combined with fixed-dose tenofovir 300 mg/emtricitabine 200 mg qd in 569 ARV-naïve HIV-1-infected patients."2.76Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study). ( Andrade-Villanueva, J; Cairns, V; Clotet, B; de Rossi, L; Domingo, P; Gellermann, HJ; Podzamczer, D; Reiss, P; Rockstroh, JK; Soriano, V; Taylor, S, 2011)
" Healthy volunteer studies have demonstrated a decrease in glucose disposal associated with dosing with specific antiretrovirals."2.75Effect of boosted fosamprenavir or lopinavir-based combinations on whole-body insulin sensitivity and lipids in treatment-naive HIV-type-1-positive men. ( Back, DJ; Boffito, M; Jackson, AG; Mandalia, S; Moyle, GJ; Randell, PA; Taylor, J; Tjia, JF, 2010)
"The use of nucleoside analogues, especially that of thymidine analogues, depletes mitochondrial DNA, which is the cause of many of the adverse effects of this family of antiretroviral drugs, among them lipodystrophy."2.44[Tenofovir as a strategy to avoid or limit adverse effects]. ( Portilla, J, 2008)
"Dyslipidemia is associated with aggressive periodontitis, a condition characterized by the rapid destruction of the periodontium."1.42Associations of apolipoprotein E and low-density lipoprotein receptor-related protein 5 polymorphisms with dyslipidemia and generalized aggressive periodontitis in a Chinese population. ( Chen, Z; Feng, X; Gao, H; Hou, J; Lu, R; Meng, H; Shi, D; Tian, Y; Wang, X; Xu, L; Zhang, L, 2015)

Research

Studies (18)

TimeframeStudies, this research(%)All Research%
pre-19901 (5.56)18.7374
1990's0 (0.00)18.2507
2000's7 (38.89)29.6817
2010's7 (38.89)24.3611
2020's3 (16.67)2.80

Authors

AuthorsStudies
Lin, HY1
Tseng, TC1
Hwang, EG1
Jung, EA1
Yoo, JJ1
Kim, SG1
Kim, YS1
Kuo, PH1
Sun, HY1
Chuang, YC1
Wu, PY1
Liu, WC1
Hung, CC1
Leohr, JK1
Luffer-Atlas, D1
Luo, MJ1
DeBrota, DJ1
Green, C1
Mabry, TE1
Suico, JG1
Pombo, M1
Olalla, J1
Del Arco, A1
De La Torre, J1
Urdiales, D1
Aguilar, A1
Prada, JL1
García-Alegría, J1
Ruiz-Mateas, F1
Gao, H1
Tian, Y1
Meng, H1
Hou, J1
Xu, L1
Zhang, L1
Shi, D1
Lu, R1
Feng, X1
Wang, X1
Chen, Z1
Portilla, J1
Miralles Alvarez, C1
Ribera Pascuet, E1
Curran, A1
Mikhail, N1
Iskander, E1
Cope, D1
Tungsiripat, M1
Kitch, D1
Glesby, MJ1
Gupta, SK1
Mellors, JW1
Moran, L1
Jones, L1
Alston-Smith, B1
Rooney, JF1
Aberg, JA1
Randell, PA1
Jackson, AG2
Boffito, M1
Back, DJ1
Tjia, JF1
Taylor, J1
Mandalia, S1
Moyle, GJ2
Podzamczer, D1
Andrade-Villanueva, J1
Clotet, B1
Taylor, S1
Rockstroh, JK1
Reiss, P2
Domingo, P2
Gellermann, HJ1
de Rossi, L1
Cairns, V1
Soriano, V1
Vrouenraets, SM1
Wit, FW1
Fernandez Garcia, E1
Allavena, C1
Raffi, F1
Jayaweera, DT1
Mauss, S1
Katlama, C1
Fisher, M1
Slama, L1
Hardy, WD1
Dejesus, E1
van Eeden, A1
Viganò, A1
Aldrovandi, GM1
Giacomet, V1
Merlo, M1
Martelli, L1
Beretta, S1
Luraschi, P1
Rombolà, G1
Mora, S1
Manfredi, R1
Llibre, JM1
Palacios, R1
Santos, J1
Pérez-Elías, MJ1
Sánchez-de la Rosa, R1
Miralles, C1
Antela, A1
Moreno, S1
Ascoli, M1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Pilot Study to Determine the Impact on Dyslipidemia of the Addition of Tenofovir to Stable Background Antiretroviral Therapy in HIV-Infected Subjects[NCT00109603]17 participants (Actual)Interventional2005-05-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

4 reviews available for adenine and Dyslipidemias

ArticleYear
Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis.
    Hepatology international, 2023, Volume: 17, Issue:4

    Topics: Adenine; Alanine; Cholesterol; Cholesterol, LDL; Dyslipidemias; Hepatitis B; Hepatitis B, Chronic; H

2023
[Tenofovir as a strategy to avoid or limit adverse effects].
    Enfermedades infecciosas y microbiologia clinica, 2008, Volume: 26 Suppl 8

    Topics: Adenine; Anemia; Anti-HIV Agents; Antimetabolites; Clinical Trials as Topic; DNA, Mitochondrial; Dou

2008
[Are all analogue combinations equal?].
    Enfermedades infecciosas y microbiologia clinica, 2008, Volume: 26 Suppl 8

    Topics: Adenine; Anti-HIV Agents; Antimetabolites; Antiretroviral Therapy, Highly Active; Cardiovascular Dis

2008
[Current role of tenofovir in clinical medicine].
    Enfermedades infecciosas y microbiologia clinica, 2008, Volume: 26 Suppl 8

    Topics: Adenine; Anti-HIV Agents; Antimetabolites; Antiretroviral Therapy, Highly Active; Chemical and Drug

2008

Trials

6 trials available for adenine and Dyslipidemias

ArticleYear
Serum Lipid and Protein Changes in Healthy Dyslipidemic Subjects Given a Selective Inhibitor of p70 S6 Kinase-1.
    Journal of clinical pharmacology, 2018, Volume: 58, Issue:4

    Topics: Adenine; Adult; Aged; Alanine Transaminase; Cholesterol, LDL; Cross-Over Studies; Dyslipidemias; Fem

2018
A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206.
    AIDS (London, England), 2010, Jul-17, Volume: 24, Issue:11

    Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cholesterol; Dyslipide

2010
Effect of boosted fosamprenavir or lopinavir-based combinations on whole-body insulin sensitivity and lipids in treatment-naive HIV-type-1-positive men.
    Antiviral therapy, 2010, Volume: 15, Issue:8

    Topics: Adenine; Adipose Tissue; Adult; Anti-HIV Agents; Blood Glucose; Carbamates; Confidence Intervals; Dr

2010
Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study).
    HIV medicine, 2011, Volume: 12, Issue:6

    Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Drug Therapy, Combination; Dyslipidemia

2011
Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients.
    HIV medicine, 2011, Volume: 12, Issue:10

    Topics: Adenine; Adult; Atazanavir Sulfate; Deoxycytidine; Drug Administration Schedule; Dyslipidemias; Emtr

2011
Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children.
    Antiviral therapy, 2005, Volume: 10, Issue:8

    Topics: Adenine; Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines;

2005

Other Studies

8 other studies available for adenine and Dyslipidemias

ArticleYear
Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles.
    Clinical and molecular hepatology, 2022, Volume: 28, Issue:2

    Topics: Adenine; Alanine; Dyslipidemias; Hepatitis B, Chronic; Humans; Tenofovir

2022
Weight gain and dyslipidemia among virally suppressed HIV-positive patients switching to co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2020, Volume: 92

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; Dyslipi

2020
Left ventricular hypertrophy detected by echocardiography in HIV-infected patients.
    European journal of internal medicine, 2013, Volume: 24, Issue:6

    Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Carba

2013
Associations of apolipoprotein E and low-density lipoprotein receptor-related protein 5 polymorphisms with dyslipidemia and generalized aggressive periodontitis in a Chinese population.
    Journal of periodontal research, 2015, Volume: 50, Issue:4

    Topics: Adenine; Adolescent; Adult; Aggressive Periodontitis; Apolipoproteins E; Blood Glucose; China; Chole

2015
Rhabdomyolysis in an HIV-infected patient on anti-retroviral therapy precipitated by high-dose pravastatin.
    Current drug safety, 2009, Volume: 4, Issue:2

    Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycytidine;

2009
Improvement of dyslipidemia during different HAART regimens: tenofovir- versus stavudine-containing antiretroviral combinations.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2006, May-01, Volume: 42, Issue:9

    Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dyslipidemias; HIV Infections; Huma

2006
Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir.
    AIDS (London, England), 2006, Jun-26, Volume: 20, Issue:10

    Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cardiovascular Disease

2006
Effects of hypocholesterolemia and chronic hormonal stimulation on sterol and steroid metabolism in a Leydig cell tumor.
    Journal of lipid research, 1981, Volume: 22, Issue:8

    Topics: Adenine; Animals; Cholesterol; Chorionic Gonadotropin; Dyslipidemias; Kinetics; Leydig Cell Tumor; M

1981